Given RIPK1’s roles in governing both immune and epithelial responses, using HSCT to cure these patients should be carefully considered, as it might ameliorate the immunodeficiency phenotype but not intestinal inflammation. This evidence concerns the gene RIPK1 and immunodeficiency disease.